Compare Citius Pharmaceuticals Inc (CTXR) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Exxon Mobil Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Exxon Mobil Corporation trades at $144.88 (market cap $601.39B). The key difference: Exxon Mobil Corporation is far larger — about 41078.6× Citius Pharmaceuticals Inc's market cap, and Exxon Mobil Corporation pays a 2.84% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | XOM | |
|---|---|---|
Market Cap | $14.64M | $601.39B |
Sector | Health | Energy |
52-Week High | $1.82 | $171.52 |
52-Week Low | $0.53 | $105.83 |
Enterprise Value | $10.86M | $640.62B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
ExxonMobil (XOM) trades at $145.09, up 4.51% today, with strong technical momentum and bullish moving average signals. The company maintains solid profitability with 7.76% net margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights Exxon's Permian Basin advantages and potential oil price spikes to $150-160 per barrel, while the company relocates its headquarters to Texas for business-friendly policies.
XOM presents a compelling investment case with analyst consensus target of $169.30 (17% upside), though risks include declining revenue trends (2025: $323.9B vs 2022: $398.7B) and oil price volatility. The stock's 24.33 P/E appears reasonable given operational strength, but investors should monitor execution on production targets and global energy market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
